CalciMedica, Inc.

CALC

US38942Q2021

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
5.48 ^USD	-1.26%		-2.14%	+91.61%

May. 13	CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	CI

CalciMedica, Inc. announced that it has received $20.252897 million in funding

February 04, 2024

On February 5, 2024, CalciMedica, Inc. closed the transaction.

Latest news about CalciMedica, Inc.

CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	Apr. 24	CI
Top Premarket Decliners	Apr. 01	MT
CalciMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
CalciMedica Inc. Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International Acute Kidney Injury At the 29th International Aki & CRRT Conference	Mar. 13	CI
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22	Feb. 16	MT
CalciMedica Gets FDA Nod for Phase 2 Trial of Acute Kidney Injury With Respiratory Failure Treatment	Feb. 13	MT
Calcimedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora? for the Treatment of Severe Acute Kidney Injury	Feb. 13	CI
CalciMedica, Inc. announced that it has received $20.252897 million in funding	Feb. 04	CI
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target	Jan. 29	MT
Calcimedica Insider Bought Shares Worth $2,515,080, According to a Recent SEC Filing	Jan. 26	MT
CalciMedica Secures $55 Million Funding Deal With Investors; Shares Gain	Jan. 22	MT
CalciMedica, Inc. announced that it expects to receive $20.4 million in funding	Jan. 18	CI
CalciMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Top Premarket Decliners	Nov. 07	MT
CalciMedica Inc. Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition	Nov. 02	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to S&P TMI Index	23-09-18	CI
CalciMedica Files $100 Million Mixed Shelf	23-08-14	MT
CalciMedica Inc. Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis	23-08-09	CI
Top Premarket Gainers	23-06-27	MT
EF Hutton Initiates CalciMedica With Buy Rating, $17 Price Target	23-06-20	MT
CalciMedica, Inc.(NasdaqGM:CALC) dropped from S&P TMI Index	23-04-03	CI
CalciMedica, Inc.(NasdaqGM:CALC) dropped from NASDAQ Composite Index	23-03-29	CI
CalciMedicaAnnounces Executive Changes	23-03-22	CI
CalciMedica, Inc.(NasdaqGM:CALC) added to NASDAQ Composite Index	23-03-22	CI

CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.45 USD

Average target price

18.67 USD

Spread / Average Target

+242.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CALCIMEDICA, INC.	+91.61%	58.53M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

CalciMedica, Inc.

Equities

CALC

US38942Q2021

Biotechnology & Medical Research

CalciMedica, Inc. announced that it has received $20.252897 million in funding

Latest news about CalciMedica, Inc.

Chart CalciMedica, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs